Company Filing History:
Years Active: 2006
Title: Armin Proell - Innovator in Migraine Treatment
Introduction
Armin Proell, an inventive mind based in Maselheim, Germany, has made significant strides in the field of pharmaceuticals. With a strong focus on migraine treatments, Proell has developed innovative compounds that aim to enhance patient care and provide relief from debilitating migraine attacks.
Latest Patents
Proell holds a patent for the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one. This invention is valuable as it serves as a structural element in CGRP-antagonists, which are particularly effective for the oral treatment of migraines. The creation of this compound represents a key development in the ongoing fight against migraine disorders.
Career Highlights
Throughout his career, Armin Proell has been associated with Boehringer Ingelheim International GmbH, a notable company in the pharmaceutical sector. His work primarily revolves around the development of new therapeutic solutions targeting migraines, showcasing his dedication to improving healthcare outcomes.
Collaborations
Proell has collaborated with esteemed colleagues such as Juergen Schnaubelt and Werner Rall. Together, they have contributed to the advancement of research and development within their organization, pooling their expertise to foster innovations that address pressing medical needs.
Conclusion
In conclusion, Armin Proell stands out as a significant innovator in the pharmaceutical industry, particularly in the realm of migraine treatment. His patent for 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one underscores his commitment to creating effective healthcare solutions. Through his collaborations and career at Boehringer Ingelheim International GmbH, Proell continues to impact the field positively, paving the way for future advancements in migraine therapy.